Invivoscribe has a long and proud history of international cooperation and partnering. In fact, we were the first US company to initiate a relationship with our European colleagues towards standardization of molecular diagnostic testing for gene rearrangements and gene translocations. Almost a decade ago we formed an alliance with the EuroClonality/ BIOMED-2 Group around their outstanding work towards standardized clonality testing.  Their seminal study: BIOMED-2 Concerted Action BMH4-CT98-3936 as published [Leukemia (2003) 17, 2257-2317] was recently followed by a second study that built on their previous work [Leukemia (2007) 21, 201-237].  Invivoscribe has become the exclusive entity tasked with commercialization of products around these extensive clinical studies. We are happy to be associated with this outstanding group of scientists and clinicians representing 47 institutions in seven European countries.

Even prior to this association we were pleased to partner with and secure a worldwide exclusive license to a series of patents held by Dr. Alexander Morley from Flinders Medical Centre in Bedford Park, South Australia. These patents covered clonality testing of the antigen receptor genes. A wonderful relationship continues to this day as we continue to work with Dr. Morley and his company, MonoQuant Pty Ltd, which is based in Adelaide, Australia on techniques for minimal disease testing.

Currently, Invivoscribe and its subsidiaries are partnering with an international array of scientists and organizations towards development, validation and commercialization of technologies for personalized molecular diagnostics and personalized molecular medicine.

In sum, Invivoscribe embraces a more seamless cooperative spirit and interaction between countries and groups to facilitate development of standardized tests and technologies. Consensus, or at least respectful understanding of differences based on the science, is important for standardization and advances in the field of personalized molecular medicine. Invivoscribe seeks collaborative interactions with scientists and partners around the world in order to identify promising areas early. It's crucial to examine emerging technologies and promising new biomarkers in molecular medicine, and pursue particular leads in a targeted way, so they can be developed and commercialized in a timely way so that they are available when they will be most useful to the community.